The Illumina Inc. Expected to Earn Q2 2017 Earnings of $0.88 Per Share (ILMN)

The Illumina Inc. Expected to Earn Q2 2017 Earnings of $0.88 Per Share (ILMN)

Illumina Inc. (NASDAQ:ILMN) – First Analysis decreased their Q2 2017 earnings per share (EPS) estimates for Illumina in a research note issued to investors on Tuesday. First Analysis analyst T. Marshbanks now anticipates that the brokerage will post earnings per share of $0.88 for the quarter, down from their prior forecast of $0.95.

Other research analysts also recently issued reports about the stock. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $167.08 target price on the stock. in a research report on Monday, July 18th. CL King started coverage on shares of Illumina in a research report on Tuesday, June 21st. They set a “buy” rating and a $165.00 price objective on the stock. Argus raised their price objective on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective on the stock in a research report on Friday, August 26th. Finally, Citigroup Inc. raised their price objective on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $157.50.

Illumina (NASDAQ:ILMN) traded up 0.775% during mid-day trading on Wednesday, hitting $137.235. 2,085,105 shares of the stock were exchanged. The company has a market cap of $20.12 billion, a P/E ratio of 46.998 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47. The company has a 50-day moving average price of $172.97 and a 200-day moving average price of $156.29.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.13. The business earned $600 million during the quarter, compared to analysts’ expectations of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.80 earnings per share.

In other news, Director Daniel Bradbury sold 600 shares of Illumina stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the completion of the sale, the director now directly owns 17,065 shares in the company, valued at $3,146,103.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Charles Dadswell sold 8,632 shares of Illumina stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $155.00, for a total transaction of $1,337,960.00. Following the sale, the senior vice president now owns 40,248 shares of the company’s stock, valued at $6,238,440. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Several large investors have recently modified their holdings of ILMN. Cleararc Capital Inc. increased its stake in shares of Illumina by 0.7% in the first quarter. Cleararc Capital Inc. now owns 3,344 shares of the life sciences company’s stock worth $542,000 after buying an additional 23 shares during the period. Tiverton Asset Management LLC purchased a new stake in shares of Illumina during the first quarter worth approximately $2,372,000. Riverhead Capital Management LLC increased its stake in shares of Illumina by 130.5% in the first quarter. Riverhead Capital Management LLC now owns 11,873 shares of the life sciences company’s stock worth $1,924,000 after buying an additional 6,723 shares during the period. Marsico Capital Management LLC increased its stake in shares of Illumina by 4.8% in the first quarter. Marsico Capital Management LLC now owns 11,898 shares of the life sciences company’s stock worth $1,929,000 after buying an additional 546 shares during the period. Finally, State Farm Mutual Automobile Insurance Co. increased its stake in shares of Illumina by 39.5% in the first quarter. State Farm Mutual Automobile Insurance Co. now owns 61,570 shares of the life sciences company’s stock worth $9,981,000 after buying an additional 17,440 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.

Illumina Company Profile

Related posts

Leave a Comment